Caso Clínico 01-2022. Mujer de 49 años con debilidad de miembros inferiores y tumoración abdominal

Kitley J, Leite M, George J, Palace J. The differential diagnosis of longitudinally extensive transverse myelitis. Mult Scler J. 2012; 18(3):271-285.

Lehnhardt FG, Impekoven P, Rubbert A, Burghaus L et al. Recurrent longitudinal myelitis as primary manifestation of SLE. Neurology. 2004; 63(10):1976.

Rabadi MH, Kundi S, Brett D Neurological pictures. Primary Sjögren syndrome presenting as neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2010; 81(2):213.

Scott AM, Yinh J, McAlindon T et al. Two cases of sarcoidosis presenting as longitudinally extensive transverse mielitis. Clin Rheumatol. 2018; 37(10):2899. Epub 2018 May 17.

Putruele AM, Legarreta CG, Limongi, Rossi SE. Tuberculous Transverse Myelitis. Clin Pulm Med. Jan 2005; 12(1): 46-52. doi: 10.1097/01. cpm.0000151496.45606.83

Beh SC, Greenberg BM, Frohman T et al. Transverse myelitis. Neurol Clin. 2013 Feb; 31(1):79-138.

Filippi M, Preziosa P, Banwell BL, et al. Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines. Brain. 2019; 142(7):1858.

Drori T, Chapman J. Diagnosis and classification of neuromyelitis optica (Devic’s syndrome). Autoimmun Rev. 2014 Apr; 13(4-5):531-3. Epub 2014 Jan 11.

Apiwattanakul M, Popescu BF, Matiello M, et al. Intractable vomiting as the initial presentation of neuromyelitis optica. Ann Neurol. 2010; 68(5):757.

Misu T, Fujihara K, Nakashima I, et al. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology. 2005 Nov; 65(9):1479-82.

Suzuki K, Nakamura T, Hashimoto K, et al. Hypothermia, hypotension, hypersomnia, and obesity associated with hypothalamic lesions in a patient positive for the anti-aquaporin 4 antibody: a case report and literature review. Arch Neurol. 2012 Oct; 69(10):1355-9.

Papadopoulos MC, Verkman AS. Aquaporin 4 and neuromyelitis optica. Lancet Neurol. 2012 Jun; 11(6):535-44. Epub 2012 May 16.

Jurynczyk M, Messina S, Woodhall MR, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain. 2017; 140(12):3128.

Flanagan EP, Keegan BM. Paraneoplastic myelopathy. Neurol Clin. 2013; 31(1):307.

Virgilio E, Vecchio D, Vercellino M, et al. Paraneoplastic neuromyelitis optica spectrum disorders: a case series. Neurol Sci. 2021; 42:2519–2522.

Krishnan C, Kaplin AI, Pardo CA, et al. Demyelinating disorders: update on transverse myelitis. Curr Neurol Neurosci Rep. 2006; 6(3):236.

Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for NMOSD. Neurology 2015; 85:177-189.

Ma X, Kermode AG, Hu X, Qiu W. NMOSD acute attack: Understanding, treatment and innovative treatment prospect. J Neuroimmunol. 2020 Nov 15; 348:577387. doi: 10.1016/j.jneuroim.2020.577387.

Huda S, Whittam D, Bhojak M, Chamberlain J, Noonan C, Jacob A. Neuromyelitis optica spectrum disorders. Clin Med (Lond). 2019 Mar; 19(2):169-176. doi: 10.7861/clinmedicine.19-2-169.

Ding M, Lang Y, Cui Li. AQP4-IgG positive paraneoplastic NMOSD: a case report and review. Brain Behav. 2021; 11e2282.

Sepúlveda M, Sola-Valls N, Escudero D, et al. Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies. Mult Scler. 2018 Nov; 24(13):1753-1759. doi: 10.1177/1352458517731914.

Beauchemin P, Iorio R, Traboulsee A, et al. Paraneoplastic Neuromyelitis Optica Spectrum Disorder: A single center cohort description with two cases of histological validation. Mult Scler Relat Disord. 2018 Feb; 20:37-42.

Annus Á, Bencsik K, Obál I, Kincses ZT, Tiszlavicz L, Höftberger R, Vécsei L. Paraneoplastic neuromyelitis optica spectrum disorder: A case report and review of the literature. J Clin Neurosci. 2018 Feb; 48:7-10. doi: 10.1016/j.jocn.2017.10.030